1. Medtech Insight

BD Pays $175M To Resolve Alaris Infusion Pump Financial Fraud Allegations

 
• By Elizabeth Orr

The settlement with the SEC closes out safety issues around the company’s Alaris infusion pumps. BD reportedly failed to alert investors or the FDA of known problems with the infusion pumps’ software for several years.

BD logo on phone screen against financial tracker background.
(Piotr Swat/Shutterstock)

Becton Dickinson and Company (BD) will pay $175m in civil penalties for allegedly failing to alert investors to safety concerns involving Alaris infusion pumps, the US Securities and Exchange Commission announced on 16 December.

Becton Dickinson repeatedly recalled the pumps due to software issues between 2016 and 2020 before ultimately removing them from the US market

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medtech Insight

More from Recalls